Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026
Alto Neuroscience, Inc. is positioned as a precision medicine innovator in CNS disorders, with major clinical readouts expected in 2026. ANRO's pipeline targets high unmet needs in depression, bipolar disorder, and schizophrenia, leveraging biomarkers to optimize drug efficacy and patient selection. The company has a strong cash runway into 2028, experienced leadership, and potential for significant upside if upcoming trials are successful.
AB or CNS: Which Is the Better Value Stock Right Now?
Investors with an interest in Financial - Investment Management stocks have likely encountered both AllianceBernstein (AB) and Cohen & Steers Inc (CNS). But which of these two companies is the best option for those looking for undervalued stocks?
AB vs. CNS: Which Stock Is the Better Value Option?
Investors with an interest in Financial - Investment Management stocks have likely encountered both AllianceBernstein (AB) and Cohen & Steers Inc (CNS). But which of these two stocks is more attractive to value investors?
Cohen & Steers: A 3.5% Yield As Commercial Real Estate Recovers
Cohen & Steers has dipped around 24% year-to-date as interest rates remained high and investor appetite for real estate and preferred equity fell. The asset manager has grown its base dividend by a healthy 9.8% CAGR over the last five years and is currently paying out a 3.5% dividend yield. Pending Fed rate cuts should help spark more investor enthusiasm for REITs and help narrow existing preferreds' discounts.
AB or CNS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Financial - Investment Management sector might want to consider either AllianceBernstein (AB) or Cohen & Steers Inc (CNS). But which of these two stocks presents investors with the better value opportunity right now?
Best High Yield Income Funds From Cohen & Steers
Cohen & Steers, Inc. offers high yield income funds paying monthly income yielding over 8%. Fund sectors include real estate, preferred securities, infrastructure, utilities, and fixed income. CNS's expertise in alternatives, active management, and reliable monthly distributions make their CEFs excellent tools for diversification and steady income.
AB vs. CNS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Financial - Investment Management sector might want to consider either AllianceBernstein (AB) or Cohen & Steers Inc (CNS). But which of these two companies is the best option for those looking for undervalued stocks?
Cohen & Steers, Inc. (CNS) Q2 2025 Earnings Call Transcript
Cohen & Steers, Inc. (NYSE:CNS ) Q2 2025 Earnings Conference Call July 18, 2025 10:00 AM ET Company Participants Brian William Heller - Senior VP & Corporate Counsel Jon Young Cheigh - President & Chief Investment Officer Joseph Martin Harvey - CEO & Director Raja Adnan Dakkuri - Executive VP & CFO Conference Call Participants John Joseph Dunn - Evercore ISI Institutional Equities, Research Division Rodrigo Beisbier Ferreira - BofA Securities, Research Division Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers Second Quarter 2025 Earnings Conference Call.
AB or CNS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Financial - Investment Management sector might want to consider either AllianceBernstein (AB) or Cohen & Steers Inc (CNS). But which of these two stocks presents investors with the better value opportunity right now?
Cohen & Steers Portfolio Of CEFs For Income
This analysis reviews Cohen & Steers' nine closed-end funds, focused on income. Fund themes include real estate, preferred securities, infrastructure, utilities, and fixed income. A balanced approach leads to risk reduction, hedging against macroeconomic volatility, ensuring stable income.
Cohen & Steers, Inc. (CNS) Q1 2025 Earnings Call Transcript
Cohen & Steers, Inc. (NYSE:CNS ) Q1 2025 Results Conference Call April 17, 2025 10:00 AM ET Company Participants Brian Heller - Senior Vice President & Deputy Corporate Counsel Raja Dakkuri - Chief Financial Officer John Cheigh - President & Chief Investment Officer Joe Harvey - Chief Executive Officer Conference Call Participants John Dunn - Evercore ISI Operator Ladies and gentlemen, thank you for standing by. Welcome to the Cohen & Steers First Quarter 2025 Earnings Conference Call.
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals, Inc. CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.
